Arjuna Capital Cuts Stock Position in Novo Nordisk A/S $NVO

Arjuna Capital cut its position in Novo Nordisk A/S (NYSE:NVO) by 3.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,443 shares of the company’s stock after selling 1,196 shares during the quarter. Arjuna Capital’s holdings in Novo Nordisk A/S were worth $2,377,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of NVO. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $30,000. NewSquare Capital LLC boosted its stake in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares in the last quarter. Disciplina Capital Management LLC grew its holdings in Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 297 shares during the last quarter. Dagco Inc. acquired a new position in shares of Novo Nordisk A/S during the first quarter worth $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S during the second quarter worth $37,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 1.9%

Shares of NVO stock opened at $48.40 on Tuesday. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $112.52. The stock has a market cap of $216.09 billion, a P/E ratio of 13.30, a P/E/G ratio of 2.33 and a beta of 0.65. The stock has a 50 day moving average of $52.56 and a 200 day moving average of $59.53. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on NVO shares. UBS Group cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. TD Cowen decreased their price target on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 19th. Morgan Stanley lowered Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and dropped their price target for the stock from $59.00 to $47.00 in a research note on Monday, September 29th. BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating on the stock in a report on Tuesday, November 25th. Finally, The Goldman Sachs Group decreased their price objective on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $56.83.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.